Skip to content

Nuvation Bio NUVB Cash Provided by (Used in) Operating Activity, Including Discontinued Operation

Cash Provided by (Used in) Operating Activity, Including Discontinued Operation at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$50.35M+47.1%
Tango Therapeutics logo
Tango TherapeuticsTNGX
-$44.36M-6.4%
Jazz Pharmaceuticals logo
Jazz PharmaceuticalsJAZZ
$408.2M-5.0%
Pfizer logo
PfizerPFE
Summit Therapeutics logo
Summit TherapeuticsSMMT
Roivant Sciences logo
Roivant SciencesROIV

Other financials

Income statement

See full
Revenue$83.2M+2,599%
Gross profit$9.8M+1,340%
Operating income$3.9M+107%
Net income$5.4M+110%
EPS (diluted)$0.01+106%

Balance sheet

See full
Cash & equivalents$125.4M+161%
Total debt$57.2M+401%
Total equity$319.6M-23.8%
Total assets$610.2M+23.9%

Cash flow

See full
Operating cash flow$5.1M+112%
CapEx$48.0K-33.3%
Free cash flow$5.0M+112%

Valuation

See full
Market cap$2.25B+150%

Profitability

See full
Gross margin54.3%+39.5pp
Operating margin-105%-52.0pp
Net margin-102.1%-50.6pp
FCF margin-93.5%-45.2pp

Returns & leverage

See full
Return on equity-39.5%-15.8pp
Debt / equity0.2×+0.2×
Current ratio7.4×-1.6×

Where this comes from

Reported directly by Nuvation Bio in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The official record: Nuvation Bio’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation?
Nuvation Bio (NUVB) reported cash provided by (used in) operating activity, including discontinued operation of $5.07M in Q1 2026.
How has Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation changed year-over-year?
Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation increased by 111.9% year-over-year, from -$42.63M to $5.07M.
What is the long-term trend for Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation?
Over 4 years (2021 to 2025), Nuvation Bio's cash provided by (used in) operating activity, including discontinued operation has grown at a 26.3% compound annual growth rate (CAGR), from -$68.19M to -$173.43M.
What does cash provided by (used in) operating activity, including discontinued operation mean?
Measures the cash generated from the company's core business operations, excluding financing and investing activities. It reflects the ability of the company to convert revenue into actual cash flow after accounting for changes in working capital.